Alternative investment giant, Blackstone to invest US$400m in gene therapy venture with Ferring

UNITED STATES – Blackstone Group Inc , one of the largest alternative invest firm in the world, has said that it will invest US$400 million in a joint venture with Swiss drug company Ferring that is working on an experimental gene therapy for bladder cancer. For its part, Ferring will invest US$170 million in the joint venture with Blackstone, dubbed FerGene, bringing the venture’s total funding to US$570 million, the companies said in a statement. FerGene is developing a gene therapy for bladder cancer patients with an aggressive form of…

Read More